CD34 and breast cancer: To ascertain whether the combination of danusertib or volasertib and AZD1775 could be an useful therapeutic strategy for BC CML patients, we assessed the effects of Aurora kinase A, PLK1 and WEE1 inhibition on the clonogenic potential of CD34+/BCR::ABL1+ cells isolated from 4 multi-TKI-resistant BC CML patients.